Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C

2012 ◽  
Vol 17 (5) ◽  
pp. 823-831 ◽  
Author(s):  
Salvatore Petta ◽  
Donatella Ferraro ◽  
Calogero Cammà ◽  
Daniela Cabibi ◽  
Antonietta Di Cristina ◽  
...  
Keyword(s):  
Vitamin D ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Virological Response ◽  
Standard Of Care ◽  
Rapid Virological Response ◽  
Genotype 1 ◽  
Vitamin D Levels

scholarly journals Rapid virological response and treatment duration for chronic hepatitis C genotype 1 patients: A randomized trial

Hepatology ◽  
2008 ◽  
Vol 47 (6) ◽  
pp. 1884-1893 ◽  
Author(s):  
Ming-Lung Yu ◽  
Chia-Yen Dai ◽  
Jee-Fu Huang ◽  
Chang-Fu Chiu ◽  
Yi-Hsin C. Yang ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Randomized Trial ◽  
Chronic Hepatitis C ◽  
Virological Response ◽  
Treatment Duration ◽  
Rapid Virological Response ◽  
Genotype 1

scholarly journals Evolution of Interferon-Based Therapy for Chronic Hepatitis C

2010 ◽  
Vol 2010 ◽  
pp. 1-12 ◽  
Author(s):  
Chun-Hao Chen ◽  
Ming-Lung Yu
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Combination Therapy ◽  
Chronic Hepatitis C ◽  
Virological Response ◽  
Standard Of Care ◽  
Rapid Virological Response ◽  
Current Standard ◽  
Sustained Response Rate ◽  
Triple Combination Therapy

Since 1986, interferon-alfa (IFN-) monotherapy has been administered for patients with chronic hepatitis C (CHC). However, sustained response rate is only about 8% to 9%. Subsequent introduction of ribavirin in combination with IFN- was a major breakthrough in the treatment of CHC. Sustained virological responses (SVRs) rate is about 30% in hepatitis C virus genotype 1 (HCV-1) patients, and is about 65% in HCV-2 or -3 patients. After 2000, pegylated interferon (PegIFN) much improved the rates of SVR. Presently, PegIFN--ribavirin combination therapy has been current standard of care for patients infected with HCV. In patients with HCV-1, treatment for 48 weeks is optimal, but 24 weeks of treatment is sufficient in HCV-2 or -3 infected patients. Clinical factors have been identified as predictors for the efficacy of the IFN-based therapy. The baseline factor most strongly predictive of an SVR is the presence of HCV-2 or -3 infections. Rapid virological response (RVR) is the single best predictor of an SVR to PegIFN-ribavirin therapy. If patients can't achieve a RVR but achieve a complete early virological response (cEVR), treatment with current standard of care can provide more than 90% SVR rate. HCV-1 patients who do not achieve an EVR should discontinue the therapy. Recent advances of protease inhibitor may contribute the development of a novel triple combination therapy.

scholarly journals Neutrophil-to-Lymphocyte Ratio as a Predictor of Response to Peginterferon plus Ribavirin Therapy for Chronic Hepatitis C

2014 ◽  
Vol 2014 ◽  
pp. 1-6 ◽  
Author(s):  
Ming-Te Kuo ◽  
Tsung-Hui Hu ◽  
Sheng-Nan Lu ◽  
Chao Hung Hung ◽  
Jing-Houng Wang ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Virological Response ◽  
White Cell Count ◽  
Neutrophil To Lymphocyte Ratio ◽  
Rapid Virological Response ◽  
Genotype 1 ◽  
Lymphocyte Ratio ◽  
Genotype 2

We aimed to determine whether neutrophil-to-lymphocyte ratio (NLR) could be a predictor of antiviral response in chronic hepatitis C patients. A total of 602 consecutive patients (genotype 1,n=263; genotype 2,n=297; others/unknown,n=42) receiving response-guided therapy with peginterferon plus ribavirin were recruited. NLR was related to clinical and virological features and to treatment outcome. Rapid virological response (RVR) and sustained virological response (SVR) were achieved in 436 (73%) and 458 (76%) of the patients, respectively. Higher NLR (≥1.42) was found to be associated with higher prevalence of DM (P=0.039) and higher hepatitis C viral load (P=0.002) and white cell count (P<0.001). NLR was significantly lower in patients with RVR and SVR compared to those without (P=0.032and 0.034, resp.). However, NLR was not an independent factor by multivariate analysis. In the subgroup analysis, higher NLR (≥1.42) (odds ratio, 0.494,P=0.038) was an independent poor predictor of SVR in genotype 2 patients but was not in genotype 1 patients. In conclusion, NLR is a simple and easily accessible marker to predict response to peginterferon plus ribavirin therapy for chronic hepatitis C genotype 2.

Sign in / Sign up

Export Citation Format

Share Document